Insmed adds two independent directors with biopharma backgrounds

Insmed Incorporated (Nasdaq: INSM) has appointed Paul Hudson and Utpal Koppikar as independent members of its board of directors, effective immediately, according to a company statement.

Hudson most recently served as chief executive officer of Sanofi S.A. from September 2019 through February 2026. Before that, he was CEO of Novartis Pharmaceuticals from 2016 to 2019 and held senior roles at AstraZeneca, including President of AstraZeneca United States. He began his career at Schering-Plough, GlaxoSmithKline UK, and Sanofi-Synthélabo UK.

Koppikar has served as chief financial officer of Verily Health Inc. since April 2023. He previously held the CFO role at Atara Biotherapeutics from 2018 to 2023 and held senior financial positions at Gilead Sciences and Amgen. He currently serves on the board of C4 Therapeutics, Inc. (Nasdaq: CCCC).

"Paul's experience leading some of the world's largest and most complex biopharma organizations, combined with his deep commercial and strategic acumen, will be invaluable as we continue to execute our global growth strategy," said Will Lewis, chair and CEO of Insmed.

Insmed is headquartered in Bridgewater, New Jersey, and operates in three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare.

You May Also Be Interested In

• Lattice Semiconductor adds two directors to its board
• Lianhe Sowell to consolidate shares 1-for-8 to maintain Nasdaq listing
• SOAR AI releases investor presentation detailing $1.17B in contracts